Novo Nordisk, CagriSema

Novo Nordisk CEO: side-effects not a problem in CagriSema study
Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug candidate CagriSema as the company considers dosage escalation and trial length for a new study.
Challenges and Confidence: Novo Nordisk's CagriSema Trial and Market Response
Novo Nordisk's CEO reassures that side-effects are not an issue in the trial of CagriSema, their next-generation obesity drug. Despite weaker-than-expected trial results, the company is optimistic about the drug's potential and plans a new study.
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors question trial protocols and transparency as Novo plans a new study.
Novo Nordisk's new CagriSema study to focus on dose escalation and trial length
Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose escalation and trial length to further show the drug's potential, after data in December disappointed the market.
Novo Nordisk's Guidance and Production Capacity in Focus -- Earnings Preview
Novo Nordisk's blockbuster GLP-1 drugs to treat type 2 diabetes and obesity, including Wegovy and Ozempic, will have continued to drive the company's growth in the quarter, Sydbank senior analyst Soren Lontoft Hansen said in a note.
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is ...
Novo Nordisk to seek regulatory approval for CagriSema obesity drug early 2026
Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
devdiscourse2h
Novo Nordisk's Bold Step: Tackling Dosage Challenges in Obesity Drug Trials
Novo Nordisk's next-gen obesity drug, CagriSema, faces trial challenges with dosage flexibility and trial length as side-effects remain controlled. Investor skepticism arose from weaker-than-expected ...
NVO Earnings: Novo Nordisk Jumps on Healthy Sales Beat Driven by Wegovy
American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales ...
Novo Nordisk Shares Have a Long Road Back from 40% Slump
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Novo Nordisk posts net profit beat as Wegovy sales jump 107% in fourth quarter
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...
Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...